Plain-English translation of NCT05640271 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that reduces inflammation in the body, can help people with sickle cell disease who are experiencing acute chest syndrome—a serious lung complication. The study will compare giving the medication right away versus waiting 48 hours, to see which timing works best.
Acute chest syndrome is a life-threatening complication of sickle cell disease that causes pain and difficulty breathing. Doctors want to know if this medication can reduce inflammation and help patients recover faster when given early in the crisis.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the medication or a placebo (salt water) right when you arrive at the hospital with chest syndrome symptoms. Two days later, you'll receive whichever one you didn't get first. During your hospital stay, doctors and nurses will collect blood samples, measure your oxygen levels, and ask about how you're feeling to compare how well each timing works.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
University of Chicago
Enrollment target
~200 participants
Started
April 2023
Primary completion
July 2026
Age range
12 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Austin Wesevich, MD
University of Chicago
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.